Organisation paid for research Program year 2025 Source: CMS Open Payments

Baylor Scott & White Research Insti

Neither a doctor nor a teaching hospital

Research payments

$203,781

42 payments

Through program year 2025, Baylor Scott & White Research Insti is reported as receiving $203,781 in research payments, across 42 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $93,384 12
2023 Research $2,300 1
2022 Research $108,097 29

Breakdown

Who paid Research payments · program years 2022–2025
  1. AbbVie, Inc. $110,397 30 payments
  2. Janssen Research & Development, LLC $93,384 12 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy $69,068 5 payments
  2. Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Patients Undergoing Open-chest Cardiac Surgery (NOVA) $41,678 11 payments
  3. A Study of the Efficacy and Safety of Risankizumab in Participants With Crohnx27s Disease $29,037 8 payments
  4. A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke $27,598 5 payments
  5. A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer $14,891 3 payments
  6. Study Comparing Intravenous (IV)x2FSubcutaneous (SC) Risankizumab to IVx2FSC Ustekinumab to Assess Change in Crohnx27s Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohnx27s Disease (CD) $7,595 3 payments
  7. A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma $7,500 2 payments
  8. A Study of the Efficacy and Safety of Risankizumab in Participants With Crohns Disease $4,490 3 payments
  9. Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed COVID19 Severe Disease $975 1 payment
  10. A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia $950 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record